Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors

被引：378

作者：

Groesch, Sabine ^{[1
]}

Maier, Thorsten Juergen ^{[1
]}

Schiffmann, Susanne ^{[1
]}

Geisslinger, Gerd ^{[1
]}

机构：

[1] Univ Frankfurt Klinikum, InstKlin Pharmakol, Pharmazentrum Frankfurt, AFES, D-60590 Frankfurt, Germany

来源：

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2006年 / 98卷 / 11期

关键词：

D O I：

10.1093/jnci/djj206

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Nonsteroidal antiinflammatory drugs (NSAIDs) appear to reduce the risk of developing cancer. One mechanism through which NSAIDs act to reduce carcinogenesis is to inhibit the activity of cyclooxygenase-2 (COX-2), an enzyme that is overexpressed in various cancer tissues. Overexpression of COX-2 increases cell proliferation and inhibits apoptosis. However, selective COX-2 inhibitors can also act through COX-independent mechanisms. In this review, we describe the COX-2-independent molecular targets of these COX-2 inhibitors and discuss how these targets may be involved in the anticarcinogenic activities of these selective COX-2 inhibitors. We also compare the concentrations of these inhibitors used in in vitro and in vivo experiments and discuss the implications of the in vitro studies for clinical management of cancer with these drugs.

引用

页码：736 / 747

页数：12

共 183 条

[1]

Achiwa H, 1999, CLIN CANCER RES, V5, P1001

[2] The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor [J].